Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic Syndromes
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 85 (planned)
- Started
- Jan 9, 2026
- Main results expected
- Feb 15, 2029
- Fully finished
- Feb 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Module 1: Number of participants with dose-limiting toxicity (DLT)
Measured over: At the end of Cycle 1 (each cycle is 28 days)
Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)
Measured over: Up to 3 years 1 month
Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)
Measured over: Up to 30 days after last dose (approximately 3 years 1 month)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07155226 · record last updated 2026-10-23 · checked 2026-11-09 15:47 UTC